Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Межрайонный центр медицинской реабилитации СПб ГБУЗ «Городская поликлиника №38». 191015, Россия, Санкт-Петербург, ул. Кавалергардская, д. 26А
Инициатива и проведение данного исследования всецело принадлежат его автору.
Список исп. литературыСкрыть список 1. Краснов В.Н., Гурович И.Я., Мосолов С.Н., Шмуклер А.Б. Психиатрическая помощь больным шизофренией. Клиническое руководство. 2-е изд. М., 2007; с. 6–7. / Krasnov V.N., Gurovich I.Ia., Mosolov S.N., Shmukler A.B. Psikhiatricheskaia pomoshch' bol'nym shizofreniei. Klinicheskoe rukovodstvo. 2-e izd. M., 2007; s. 6–7.[in Russian] 2 Buchanan RW, Javitt DC, Marder SR et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007; 164: 1593–602. 3. Lieberman J, Papadakis K, Csernansky J et al. A randomized, placebo controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 2009; 34 (1): 1322–9. 4. De Lucena D, Fernandes BS, Berk M et al. Improvement of negative and positive symptoms in treatment refractory schizophrenia: A double blind, randomized, placebo controlled trial with memantine as add on therapy to clozapine. J Clin Psychiatry 2009; 70 (10): 1416–23. 5. Krysinska K, Heller TS, De Leo D. Suicide and deliberate self-harm in personality disorders. Curr Opin Psychiatry 2006; 19 (95): 101. 6. Clinton SM, Meador-Woodruff JH. Abnormalities of the NMDA Receptor and Associated Intracellular Molecules in the Thalamus in Schizophrenia and Bipolar Disorder. Neuropsychopharmacology 2004; 29: 1353–62. 7. Gilmour G, Pioli EY, Dix SL et al. Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for "NMDA antagonist modeling" of schizophrenia. Psychopharmacology (Berl) 2009; 205: 203–16. 8. Gilmour G, Dix S, Fellini L et al. NMDA receptors, cognition and schizophrenia – testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology 2012; 62: 1401–12. 9. Ghaleiha A, Asadabadi M, Mohammadi M et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: A randomized, doubleblind, placebo controlled trial. Int J Neuropsychopharmacol First View 2012; 1: 1–7. 10. Koola MM, Buchanan RW, Pillai A et al. Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia. Schizophr Res 2014; 157 (0): 84–9. 11. Rezaei F, Karimi M, Seddighi S et al. Memantine add 2 on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized, double blind, placebo controlled study. J Clin Psychopharmacol 2013; 33 (3): 336–42. 12. Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol 2006; 6: 61–7. 13. Lee JG, Lee SW et al. Adjunctive Memantine Therapy for Cognitive Impairment in Chronic Schizophrenia: A Placebo 2 Controlled Pilot Study. Psychiatry Investig 2012; 9 (2): 166–73. 14. Haw C, Hawton K, Sutton L et al. Schizophrenia and deliberate self-harm: a systematic review of risk factors. Suicide Life Threat Behav 2005; 35: 50–62. 15. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nature Rev Neurosci 2005; 6: 312–24. 16. Paraschakis A. Tackling Negative Symptoms of Schizophrenia with Memantine. Case Rep Psychiatry 2014; Article ID 384783: p. 3. 17. Rabe-Jablonska J, Mirek M, Pawelczyk T. Risk factors of schizophrenia development in patients with amphetamines dependence and psychosis (amphetamine-induced psychosis and schizophrenia), and without psychosis. Psychiatr Pol 2012; 46: 571–84. 18. Sani G, Serra G, Kotzalidis G et al. The role of memantine in the treatment of psychiatric disorders other than the dementias: A review of current preclinical and clinical evidence. CNS Drugs 2012; 26 (8): 663–90. 19. Symonds CS, Taylor S, Tippins V, Turkington D. Violent self-harm in schizophrenia. Suicide Life Threat Behav 2006; 36: 44–9. 20. Buchanan RW. Glutamatergic agents for the treatment of schizophrenia. Eur Neuropsychopharmacol 2014; 24 (2): 115. 21. Hypothesis of Schizophrenia and its Implication for Treatmentment. Neuropsychopharmacol Rev 2012; 37: 4–15. 22. Kishi T, Iwata N. NMDA receptor antagonists interventions in schizo-phrenia: metaanalysis of randomized, placebo controlled trials. J Psychiatr Res 2013; 47 (9): 1143. 23. Kotermanski S, Johnson J, Thiels E. Comparison of behavioral effects of the NMDA receptor channel blockers memantine and ketamine in rats. Pharmacol Biochem Behav 2013; 109: 67–76. 24. Palmer B, Pankratz V, Bostwick J. The lifetime risk of suicide in schizo-phrenia: a reexamination. Arch Gen Psychiatry 2005; 62: 247–53. 25. Uribe E, Landaeta J,Wix R, Eblen A. Memantine Reverses Social Withdrawal Induced by Ketamine in Rats. Exp Neurobiol 2013; 22 (1): 18–22.